Brief: Merit Medical Systems Q2 Adjusted EPS USD 1.01 Vs. IBES Estimate USD 0.85

Merit Medical Systems

30/07/2025 21:05

Overview

Merit Medical Q2 revenue rises 13.2% yr/yr, beating analyst expectations

Adjusted EPS for Q2 up 9.8%, exceeding analyst estimates

Co acquired Biolife Delaware

Appoints Martha Aronson as new CEO, effective October 3, 2025

Outlook

Merit expects 2025 revenue between $1.495 bln and $1.507 bln

Company forecasts 2025 non-GAAP EPS of $3.52 to $3.72

Merit anticipates cardiovascular revenue of $1.423 bln to $1.434 bln

Company projects endoscopy revenue of $72 mln to $73 mln

Result Drivers

REVENUE GROWTH - Revenue increased by 13.2% to $382.5 mln, driven by a 12.5% rise in constant currency revenue and a 6.7% increase in organic revenue

OPERATING MARGIN - Non-GAAP operating margin improved to 21.2% from 20.1% in the prior year period

ACQUISITION IMPACT - Acquisition of Biolife Delaware, a hemostatic devices manufacturer

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Beat
$382.50 mln
$373.40 mln (11 Analysts)
Q2 Adjusted EPS
Beat
$1.01
$0.85 (10 Analysts)
Q2 EPS
$0.54
Q2 Adjusted Net Income
Beat
$61 mln
$51.90 mln (9 Analysts)

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

Wall Street's median 12-month price target for Merit Medical Systems Inc is $108.00, about 23.3% above its July 29 closing price of $82.87

The stock recently traded at 23 times the next 12-month earnings vs. a P/E of 28 three months ago

Press Release: ID:nGNX9p9ysd

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)